Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program

In August 2006, the Australian government approved subsidized trastuzumab therapy for human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, and it was mandated that HER2 testing should be performed using in situ hybridization (ISH) rather than immunohistochemistry (IHC). Here...

Descripción completa

Detalles Bibliográficos
Autores principales: Bilous, Michael, Morey, Adrienne L., Armes, Jane E., Bell, Richard, Button, Peter H., Cummings, Margaret C., Fox, Stephen B., Francis, Glenn D., Waite, Brigid, McCue, Glenda, Raymond, Wendy A., Robbins, Peter D., Farshid, Gelareh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2012
Materias:
Preclinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401497/
https://www.ncbi.nlm.nih.gov/pubmed/22678156
http://dx.doi.org/10.1007/s10549-012-2093-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401497/
https://www.ncbi.nlm.nih.gov/pubmed/22678156
http://dx.doi.org/10.1007/s10549-012-2093-6

Ejemplares similares